IC4 Flashcards

1
Q

Common clinical indications for macrolides

A

atypical microbes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

Common clinical indications for macrolides

A

atypical microbes, respiratory tract infections (CAP), Chlamydial infections, Diphtheria, H.pylori (Clarithromycin/Azithromycin + omeprazole +amoxicillin), Mycobacterial infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which macrolides is usually destroyed by gastric acid and thus administered in either enteric-coated tablets or esterified forms?

A

Erythromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ROA for macrolides

A

IV and Oral except clarithromycin (Oral only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Adverse effects of macrolides

A
  • Gastric distress and motility (Less with clarithromycin and azithromycin than erythromycin (motilin agonist))
  • Hepatotoxicity: Cholestatic jaundice
  • Ototoxicity
  • may prolong the QT interval and should be used with caution in those patients with pro-arrhythmic conditions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

which other drug can antagonise action of clindamycin?

A

Although clindamycin and erythromycin are not structurally related, they act at sites of proximity, and can antagonise each others action.

Cross resistance with macrolides due to (erm) methylases can also occur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is clindamycin useful against?

A

anaerobic infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

dosage form for clindamycin

A

Oral and IV; topical solution, gel, or lotion and vaginal cream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Contraindication for clindamycin

A

CDAD, pseudomembranous colitis / ulcerative colitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOA of Resistance in clindamycin

A
  1. Alteration of the 50S ribosomal subunit by aa substitution
  2. Alteration in the 23S ribosomal RNA subunit by methylation and nucleotidylation of the hydroxyl group of clindamycin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Activity of linezolid

A

Gram positive only (incl MRSA, VRE, VRSA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of linezolid

A

Binds the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dosage form for linezolid

A

Oral and IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MOA of Resistance to linezolid

A
  1. Mutations in the 23S ribosomal RNA is the major cause of linezolid resistance in VRE and MRSA.
  2. Resistance can also be conferred by the cfr rRNA methyltransferase against lincosamides and oxazolidinones
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adverse effects of linezolid

A
  1. GI effects
  2. Bone Marrow Suppression: Thrombocytopenia has been reported in patients taking the drug for >10 days. (Need to monitor blood counts)
  3. may lead to serotonin syndrome if given concomitantly with selective serotonin reuptake inhibitors, or MAO inhibitors (reversible)
  4. Irreversible peripheral neuropathies and optic neuritis (causing blindness) have been associated with > 28 days of use
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Contraindication for linezolid

A
  1. Treatment of catheter-related bloodstream infections or catheter-site infections
  2. Do not use within two weeks of MAO inhibitors, e.g., phenelzine
  3. Tyramine-containing foods and serotonergic drugs, as these may precipitate a hypertensive crisis.

Examples of tyramine-containing foods include aged cheese, cured or smoked meats, draft beer, fava beans, and soy products.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MOA for fluoroquinolones

A
  1. targets DNA gyrase, primarily in Gram-negative bacteria
  2. targets topoisomerase IV in Gram-positive bacteria

to inhibit DNA replication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clearance method for various fluoroquinolones

A

Levofloxacin/ Ciprofloxain: Renal CL
Moxifloxacin: Hepatic CL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Generation for various fluoroquinolones

A

2nd: Ciprofloxacin
3rd: Levofloxacin, Moxifloxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

3rd gen fluoroquinolones vs 2nd gen advantage

A
  • Better coverage against Gram positive organisms, especially S. pneumoniae
  • Increased coverage against atypical pathogens such as Mycoplasma pneumoniae and Chlamydia pneumoniae

Hence 3rd gen known as respiratory quinolones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Adverse effects of fluoroquinolones

A
  1. GI related (most common) - nausea, vomiting, and diarrhoea
  2. Risk of dysglycaemia especially in diabetic patients
  3. Aortic dissections or ruptures of an aortic aneurysm - rare
  4. Increased risk of C. diff colitis as they clear the bowel flora, esp with
    ciprofloxacin
  5. Headache and dizziness or light headedness may occur. Thus, patients with CNS disorders, such as epilepsy, should be treated cautiously with these drugs.
  6. phototoxicity
  7. An increased risk of tendinitis or tendon rupture may occur with systemic fluoroquinolone use.
  8. may prolong the QTc interval (more common with third gen)
  9. Peripheral Neuropathy with systemic use
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Contraindication for fluoroquinolones

A
  1. Not recommended for infants or children < 18 years of age as they have been shown to cause joint problems (arthropathy) in young animals.
  2. Ciprofloxacin in lactation
  3. Patients with myasthenia gravis because it may exacerbate muscle weaknesses.
  4. G6PD deficiency

Quinolones may also raise the serum levels of warfarin, and cyclosporine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Contraindication for sulfonamide

A

Due to the danger of kernicterus, sulfa drugs should be avoided in < 2 months of age, and in pregnant women at term.

22
Q

Drug potentiation for sulfonamide

A

Transient potentiation of the anticoagulant effect of warfarin

23
Q

Adverse effects of sulfonamide

A
  1. Crystalluria
  2. Hypersensitivity
  3. Hematopoietic disturbances - haemolytic anaemia, G6PD deficiency
  4. Kernicterus
24
Q

How to prevent crystalluria in sulfonamide use?

A

Hydration and alkalinisation of urine can prevent the problem by reducing the concentration of drug and promoting its ionization.

25
Q

MOA for trimethorpim

A

Trimethoprim inhibits the reduction of dihydrofolic acid by dihydrofolate reductase to its active form.

This leads to a decreased availability of the tetrahydrofolate cofactors required for purine, pyrimidine, and amino acid synthesis.

26
Q

MOA for sulfonamide

A

Sulfonamides are competitive inhibitors of dihydropteroate synthase, the bacterial enzyme responsible for the incorporation of para- aminobenzoic acid (PABA) into dihydropteroic acid, the immediate precursor of folic acid

27
Q

Sensitive microorganisms for sulfonamide

A

those that must synthesize their own folic acid; bacteria that can use preformed folate are not affected

28
Q

Activity of trimethoprim and sulfonamide

A

Enterobacter spp, E.coli, Klebsiella pneumoniae

29
Q

Clearance method for sulfonamide/ trimethoprim

A

Renal CL

30
Q

Which grps of patient have incr risk of folic acid deficiency?

A

Pregnant women, those having very poor diets

31
Q

Management of folic acid deficiency

A

Folinic acid (readily converted to tetrahydrofolic acid)

32
Q

Composition for Cotrimoxazole

A

1 Trimethoprim: 5 sulfamethoxazole

33
Q

Trade names for cotrimoxazole

A

Bactrim; Septra

34
Q

Which grp of patients experience more adverse reactions to cotrimoxazole such as fever, rashes, hyperkalaemia, hyponatremia and diarrhea?

A

Immunocompromised patients, such as those with HIV/AIDS

35
Q

Activity of cotrimoxazole

A
  1. UTIs, E.coli. Low dose TMP-SMX can also be given to women for recurrent UTI as prophylaxis.
  2. Respiratory tract infections caused by Haemophilus sp, Moraxella catarrhalis and Klebsiella pneumonia
  3. MRSA and community-acquired skin and soft tissue infections caused by this organism.
  4. Pneumocystis pneumonia caused by Pneumocystis jiroveci
36
Q

Adverse effects of cotrimoxazole

A
  1. Skin reactions like rash are common.
  2. Photosensitivity
  3. Nausea and vomiting are the most common gastrointestinal adverse effects.
  4. Glossitis and stomatitis can occur.
  5. Hemolytic anemia may occur in patients with G6PD deficiency due to the sulfamethoxazole component.
  6. Megaloblastic anemia, leukopenia, and thrombocytopenia may occur and can be fatal.
  7. Use with caution in pregnancy as it can cause folate deficiency
37
Q

DDI with cotrimoxazole

A

Can increase the half life of phenytoin, enhance the effect of warfarin.

38
Q

MOA for nitrofurantoin

A

Reduced in bacteria to a highly active intermediate that inhibits various enzymes and disrupt the synthesis of proteins, DNA, RNA, and metabolic processes.

39
Q

Activity of nitrofurantoin

A

E. coli and enterococcus

40
Q

Which bacteria is nitrofurantoin NOT active against?

A

Proteus and Pseudomonas and many species of Enterobacter and Klebsiella are resistant

41
Q

dosage form for nitrofurantoin

A

oral

42
Q

indication for nitrofurantoin

A

prevention and treatment of lower UTIs (acute lower UTI, prophylaxis of lower UTI)

43
Q

Low / high pH enhances activity of nitrofurantoin

A

Low; Acidic urine (pH < 5.5) greatly enhances drug activity

44
Q

Adverse effects of nitrofurantoin

A
  1. Nausea, vomiting, and diarrhea are common. Macrocrystalline preparation is
    better tolerated.
  2. Hypersensitivity reactions occasionally occur e.g. chills and fever,
  3. Leukopenia, hemolytic anemia (a/w G6PD deficiency),
  4. Cholestatic jaundice, and hepatocellular damage. (Its nitro-reductive metabolism produces injurious oxidative free radicals which can damage hepatocytes) (rare)
  5. Elderly patients are especially susceptible to the pulmonary toxicity of nitrofurantoin.
  6. Peripheral neuropathies are most likely to occur in patients with impaired renal function and in persons on long-continued treatment. (rare)
  7. Often there is a prolonged incubation period to onset of liver injury due to nitrofurantoin, and this frequently leads to mistaken or delayed diagnosis.
  8. colours the urine brown
45
Q

contraindication for nitrofurantoin

A
  1. Individuals with impaired renal function (creatinine clearance <40 mL/minute)
  2. Pregnant women (38 to 42 weeks gestation), during labor and delivery, or when
    the start of labor is imminent
  3. Infants <1 month of age should not receive nitrofurantoin
46
Q

structure of anti-protozoal agent

A

unicellular eukaryotes

47
Q

what is amebiasis caused by?

A

Entamoeba histolytica

48
Q

what kind of agent does metronidazole belong to?

A

anti-protozoal agent

49
Q

MOA of metronidazole

A

Nitro group of metronidazole serves as an electron acceptor, forming cytotoxic free radicals that results in protein and DNA damage, and death of the E. histolytica trophozoites

50
Q

Activity of metronidazole

A

Amebic infections, anaerobes, H. pylori, surgical prophylaxis

51
Q

Clearance method for metronidazole

A

Hepatic

52
Q

DDI with metronidazole

A

warfarin

53
Q

contraindication for metronidazole

A

avoid in pregnancy (1st trimester) & alcohol

54
Q

adverse effects of metronidazole

A
  1. GI: nausea, vomiting, epigastric distress, and abdominal cramps.
  2. An unpleasant, metallic taste is commonly experienced.
  3. Oral moniliasis (yeast infection of the mouth)
  4. Central and Peripheral Nervous System Effects: Convulsive seizures, optic and peripheral neuropathy. Rare but discontinue the drug if it happens.